In the past week or so there was some question about IPIX's agreement with Alfasigma as to rights granted to AS. The following is a copy from the company website under "About", then "Collaborations":
On July 22, 2019, Innovation completed a license agreement with Alfasigma S.p.A, granting the company exclusive rights to develop and commercialize locally-administered Brilacidin (e.g., foam, enema, gel), on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) in Inflammatory Bowel Disease (IBD). As part of the agreement, Innovation is eligible to receive over $24M in initial and milestone-based payments, and a 6 percent royalty (net sales) based on the successful marketing of Brilacidin for UP/UPS. The agreement also includes a Right of First Refusal for Brilacidin for the treatment of more extensive forms of IBD, such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for Brilacidin in other Gastrointestinal indications.
Market Data 
Markets 
AI
